ReviewDialogues in clinical neuroscience2007
Cannabinoids in health and disease.
Review in Dialogues in clinical neuroscience, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 2 syntheses or guidelines pooled it, 221 citations in OpenAlex.
- Cannabinoid interventions for improving cachexia outcomes in cancer: a systematic review and meta-analysis.Journal of cachexia, sarcopenia and muscle · 2022Pooled it
- Interventions for chronic pruritus of unknown origin.The Cochrane database of systematic reviews · 2020Pooled it
- Postoperative complications following mastopexy and reduction mammaplasty in patients with cannabis use disorder: a propensity-matched cohort study.JPRAS open · 2026Article
- Acute Ultra Low Dose THC Attenuates Anxiety-Like Behavior in a Mouse Model for Major-Depressive Disorder.Journal of molecular neuroscience : MN · 2026Article
- Emerging roles of cannabinoid pathways in renal injury and repair.Frontiers in pharmacology · 2026Review
- Endocannabinoid system modulation in bruxism: a neurobiological hypothesis and translational model of ECS-targeted intervention.Frontiers in neuroscience · 2026Article
- Bioinformatics differential expression analysis of the effect of cannabidiol in chronic myeloid leukaemia cell line.Global medical genetics · 2025Article
- Psychoactive substances: novel molecular insights and therapeutic potential for Alzheimer's disease.Translational neurodegeneration · 2025Review
- The Impact of Cannabidiol (CBD) on Lipid Absorption and Lymphatic Transport in Rats.Nutrients · 2025Article
- High-Performance Liquid Chromatography with DAD Detection for the Determination of Cannabinoids in Commercial Veterinary CBD Oil.Pharmacy (Basel, Switzerland) · 2024Article
- Prevalence of Metabolic Syndrome Among Emerging Adult Cannabis Users by Race/Ethnicity: Analysis of the 2009-2018 National Health and Nutrition Examination Surveys.American journal of medicine open · 2024Article
- Cannabidiol Exposure During Rat Pregnancy Leads to Labyrinth-Specific Vascular Defects in the Placenta and Reduced Fetal Growth.Cannabis and cannabinoid research · 2024Article
- Charting the Cannabis plant chemical space with computational metabolomics.Metabolomics : Official journal of the Metabolomic Society · 2024Article
- Evaluation of dispensaries' cannabis flowers for accuracy of labeling of cannabinoids content.Journal of cannabis research · 2024Article
- Cannabinoid-Induced Stereoselective Inhibition of R-S-Oxazepam Glucuronidation: Cannabinoid-Oxazepam Drug Interactions.Pharmaceutics · 2024Article
- Phytocannabinoids as Potential Multitargeting Neuroprotectants in Alzheimer's Disease.Current drug research reviews · 2024Review
- Exploring the antifungal potential ofFrontiers in chemistry · 2024Article
- Multi-modal transcriptomics: integrating machine learning and convolutional neural networks to identify immune biomarkers in atherosclerosis.Frontiers in cardiovascular medicine · 2024Article
- Molecular pharmacology of the onco-TRP channel TRPV6.Channels (Austin, Tex.) · 2023Review
- Poly(ethylene glycol)-b-poly(epsilon-caprolactone) nanoparticles as a platform for the improved oral delivery of cannabidiol.Drug delivery and translational research · 2023Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cannabis sativa L. preparations have been used in medicine for millenia. However, concern over the dangers of abuse led to the banning of the medicinal use of marijuana in most countries in the 1930s. Only recently, marijuana and individual natural and synthetic cannabinoid receptor agonists and antagonists, as well as chemically related compounds, whose mechanism of action is still obscure, have come back to being considered of therapeutic value. However, their use is highly restricted. Despite the mild addiction to cannabis and the possible enhancement of addiction to other substances of abuse, when combined with cannabis, the therapeutic value of cannabinoids is too high to be put aside. Numerous diseases, such as anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Tourette's syndrome, Alzheimer's disease), epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders, to name just a few, are being treated or have the potential to be treated by cannabinoid agonists/antagonists/cannabinoid-related compounds. In view of the very low toxicity and the generally benign side effects of this group of compounds, neglecting or denying their clinical potential is unacceptable--instead, we need to work on the development of more selective cannabinoid receptor agonists/antagonists and related compounds, as well as on novel drugs of this family with better selectivity, distribution patterns, and pharmacokinetics, and--in cases where it is impossible to separate the desired clinical action and the psychoactivity--just to monitor these side effects carefully.
Indexed as
Identifiers
18286801PMC3202504W2101599025What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.